Commentary: New Value Frameworks Miss the Point
In his latest Forbes.com commentary, Precision Health Economics co-founder Tomas Philipson (along with Precision co-author Jason Shafrin) addresses the development of new value frameworks, and how both physicians and patients are at risk.
Top 100 Agencies 2016 (precisioneffect) – Medical Marketing & Media
Precision Medicine Group is proud to announce that precisioneffect has been named one of the top 100 agencies of 2016 by Medical Marketing & Media.
Insider Q&A: A Model for More Rational Drug Prices – Associated Press
Precision Health Economics’ Darius Lakdawalla speaks with the AP’s Matthew Perrone and offers some guidelines for drug pricing.
Commentary: Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?
Rick Lifsitz and Larry Blandford address market access for novel Alzheimer’s treatments in a new commentary for Journal of Clinical Pathways
Real World Superiority Data May Not Be Enough To Boost GSK’s Breo In COPD – The Pink Sheet
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.